Temple University Health System’s preparations for and treatment of patients amidst the coronavirus pandemic continue to be part of the media’s COVID-19 coverage.
- Jason C. Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, Clinical Professor and Director of the Postgraduate Year Two Infectious Diseases Residency at the Temple University School of Pharmacy and Clinical Pharmacist Specialist in Infectious Diseases at Temple University Hospital, offered insight to the Wall Street Journal on Paxlovid, and how it has become the oral antiviral medication of choice for COVID-19. The Wall Street Journal article was picked up by MSN.com.
- Dr. Gallagher also offered insight to Reuters on Paxlovid and rebound symptoms.
- Joshua Cooper, MD, FACC, FHRS, Director of Cardiac Electrophysiology at Temple University Hospital and Professor of Medicine at the Lewis Katz School of Medicine at Temple University, spoke with Marketplace about the shortages of an injectable dye used in certain medical scans following a production shutdown overseas due to COVID-19. Temple is following recommendations of national medical societies and making every effort to provide patients necessary and appropriate care without interruption.